📣 We are excited to announce the launch of a new production area designed for the synthesis of highly potent Active Pharmaceutical Ingredients (HPAPIs).

This expansion proves our commitment to providing specialized solutions for the development and manufacturing of life-saving medications. Our focus within this new facility will be the production of ifosfamide 💊

CEP (Certificate of Suitability) for ifosfamide has already been granted to TZF Polfa. We are diligently working towards achieving EU GMP certification for this critical API by the end of 2024 ⏳

„This expansion strengthens TZF’s strategy towards high potent drugs market and allows us to contribute even more effectively to the global pharmaceutical landscape” – said Kamil Garbera.